|
Company:
|
CORMEDIX INC. (CRMD)
|
|
Form Type:
|
SC 13G/A
|
|
Filing Date:
|
2/14/2023
|
|
CIK:
|
0001410098
|
|
Address:
|
300 CONNELL DRIVE
SUITE 4200
|
|
City, State, Zip:
|
BERKELEY HEIGHTS, New Jersey 07922
|
|
Telephone:
|
908-517-9500
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$4.89
|
Change:
0.12 (2.52%)
|
Trade Time:
May 26
|
Market Cap:
$221.90M
|
|
|
|
|
|
|
Description of Business
|
|
We are a biopharmaceutical company focused on developing and commercializing
therapeutic products for the prevention and treatment of life-threatening
diseases and conditions.
Our primary focus is on the development of our lead product candidate,
DefenCath(TM), for potential commercialization in the United States, or U.S., and
other key markets. We have in-licensed the worldwide rights to develop and
commercialize DefenCath and Neutrolin®. The name DefenCath is the U.S.
proprietary name conditionally approved by the U.S. Food and Drug
Administration, or FDA, while the name Neutrolin was used in the European Union,
or EU, and other territories where we received CE-Mark approval for the
commercial distribution of Neutrolin as a catheter lock solution, or CLS,
regulated as a medical device.
|
|
|
|